Peptide library / Heart & blood / Motixafortide
Motixafortide
A CXCR4 blocker that pushes stem cells into the blood for collection before transplant.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Stem cell mobilization in multiple myelomaFDA approved
How it is thought to work
Motixafortide blocks CXCR4, which normally anchors stem cells in the bone marrow, so they move into the blood.
What the evidence shows
The GENESIS trial showed more patients collected enough stem cells in one session than with standard mobilization.
Safety and unknowns
Injection site reactions and allergic-type reactions.
Regulatory status
FDA-approved as Aphexda in 2023.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Nesiritide
FDA-approvedA recombinant B-type natriuretic peptide once widely used in acute heart failure.
Pegcetacoplan
FDA-approvedA pegylated cyclic peptide that blocks complement C3, approved for a rare blood disorder and for an eye disease.
Icatibant
FDA-approvedA ten amino acid bradykinin blocker for attacks of hereditary angioedema.
General information, not medical advice. Do not buy or inject unregulated peptides.